<DOC>
	<DOCNO>NCT01867736</DOCNO>
	<brief_summary>A prospective , multicentric , randomize control trial ass safety performance Passeo-18 Lux Paclitaxel release PTA balloon catheter versus uncoated Passeo 18 PTA balloon catheter treatment stenosis , restenosis occlusion infrapopliteal artery .</brief_summary>
	<brief_title>BIOLUX P-II First-in-Man Study Compare Passeo-18 Lux DRB Against POBA Infrapopliteal Arteries</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>1 . Subject provide write informed consent . 2 . Subject willing able comply followup evaluation . 3 . Subject ≥ 18 year old . 4 . Single sequential de novo restenotic lesion ( stenosis ≥ 70 % diameter reduction occlusion ) infrapopliteal artery ≥ 30 mm . Lesions extend beyond ankle joint . 5 . A maximum 2 different vessel treat : successful wire crossing require first target vessel randomization occur . 6 . Subject PAD critical limb ischemia accord current guideline need urgent revascularization relieve symptom improve walk capacity . 7 . Reference Vessel Diameter ( RVD ) 2 4 mm , base visual estimation . 8 . Inflow free flowlimiting lesion confirm angiography . Patients flowlimiting inflow lesion ( &gt; 50 % stenosis ) include lesion ( ) treat successfully index procedure , maximum residual stenosis 30 % per visual assessment . 9 . At least one nonoccluded crural vessel angiographically document runoff foot . 10 . Successful wire cross lesion . 1 . Flowlimiting ( &gt; 50 % DS ) inflow lesion proximal target lesion , leave untreated . 2 . Failure obtain &lt; 30 % residual stenosis preexist haemodynamically significant ( &gt; 50 % DS ) inflow lesion ( DEB DES allow treatment inflow lesion ) . 3 . Infrapopliteal lesion extend beyond ankle joint involve crural vessel . 4 . Acute thrombus target vessel ( eg complication inflow lesion treatment ) document angiogram , treat successfully prior enrolment ) . 5 . Planned major amputation ankle target limb , plan major surgery within 30 day postprocedure . 6 . Previous bypass surgery target vessel . 7 . Previously implant stent target lesion . 8 . Haemorrhagic diathesis coagulopathy disorder gastrointestinal ulceration cerebral disorder would restrict prescription dual antiplatelet therapy . 9 . Subject hepatic failure , deep vein thrombosis , thrombophlebitis , systemic lupus erythematous subject immunosuppressant therapy . 10 . Subject acute MI ≤ 3 month . 11 . Renal failure creatinine ≥ 2,5 mg/dl , except patient currently regular dialysis . 12 . Phenprocoumon intake , except patient treat Arterial Fibrillation . For patient Phenprocoumon treatment interrupt restarted treatment Dual Antiplatelet Therapy 4 week post procedure . 13 . Known allergy contrast medium use angiography control premedication steroid and/or antihistaminica . 14 . Allergy , intolerance hypersensitivity Paclitaxel relate compound and/or delivery matrix nButyryl trinhexyl citrate ( BTHC ) . 15 . Co morbid condition limit life expectancy ≤ 1 year . 16 . Patients active treatment cancer ; Patients , successfully treat cancer past , include . 17 . Subject participate another clinical device trial primary endpoint yet reach . 18 . Pregnant and/or breastfeed female female intend become pregnant time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Stenosis</keyword>
	<keyword>Occlusions</keyword>
	<keyword>Infrapopliteal artery</keyword>
	<keyword>Below knee artery</keyword>
	<keyword>PTA</keyword>
	<keyword>POBA</keyword>
	<keyword>DRB</keyword>
</DOC>